Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease.
Cancer
Secukinumab
Spondyloarthritis
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
20 Mar 2024
20 Mar 2024
Historique:
received:
28
12
2023
accepted:
26
02
2024
medline:
20
3
2024
pubmed:
20
3
2024
entrez:
20
3
2024
Statut:
aheadofprint
Résumé
Secukinumab is a monoclonal antibody directed against interleukin-17 approved for the treatment of psoriasis and spondyloarthritis. The favorable oncological profile of secukinumab in patients with a history of malignancy has been shown in patients with psoriasis. However, systematic data to this regard have not been published yet for patients with spondyloarthritis. The objective of the present study was to evaluate the oncological safety of secukinumab in patients affected by this group of diseases. We performed a retrospective study in which we identified from our cohort patients with spondyloarthritis treated with secukinumab and with a history of malignancy. These patients' baseline demographic, treatment, rheumatological, and oncological data were collected. The neoplastic outcome (i.e., cancer recurrence or progression) after secukinumab start was then analyzed. Our study included 22 patients with spondyloarthritis. The most frequently reported oncological diagnosis was breast cancer (9 [41%] patients). Secukinumab was started after a median of 24 months following cancer diagnosis. At this time point, all but three patients were in oncological remission. No case of cancer relapse or progression was recorded over a median follow-up of 30 months. In the largest cohort reported to date to this regard, secukinumab was not associated with oncological recurrence or progression in patients with spondyloarthritis with a history of malignancy. Secukinumab may, therefore, represent a safe option in this clinical scenario.
Identifiants
pubmed: 38506924
doi: 10.1007/s00296-024-05571-y
pii: 10.1007/s00296-024-05571-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bass AR, Abdel-Wahab N, Reid PD, Sparks JA, Calabrese C, Jannat-Khah DP et al (2023) Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis 82(7):920–926
doi: 10.1136/ard-2023-223885
pubmed: 37019614
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316–326
doi: 10.1056/NEJMoa2109927
pubmed: 35081280
Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. J Exp Med 206(7):1457
doi: 10.1084/jem.20090207
pubmed: 19564351
pmcid: 2715087
Zhao J, Chen X, Herjan T, Li X (2020) Cytokines focus: the role of interleukin-17 in tumor development and progression. J Exp Med 217(1):e20190297
doi: 10.1084/jem.20190297
pubmed: 31727782
Chen YS, Huang TH, Liu CL, Chen HS, Lee MH, Chen HW et al (2019) Locally targeting the IL-17/IL-17RA axis reduced tumor growth in a murine B16F10 melanoma model. Hum Gene Ther 30(3):273–285
doi: 10.1089/hum.2018.104
pubmed: 30079767
Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W et al (2021) The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol 185(5):935–944
doi: 10.1111/bjd.20136
pubmed: 33829482
Li PH, Wai Chan SC, Lau CS, Yan Seto MT, Chung HY (2022) Conventional and biologic disease-modifying antirheumatic drugs are not associated with increase in or progression of cervical neoplasia among patients with spondyloarthritis. J Clin Rheumatol 28(1):E63–E68
doi: 10.1097/RHU.0000000000001590
pubmed: 33105316
Pellegrini C, Esposito M, Rossi E, Gisondi P, Piaserico S, Dapavo P et al (2022) Secukinumab in patients with psoriasis and a personal history of malignancy: a multicenter real-life observational study. Dermatol Ther (Heidelb). 12(11):2613
doi: 10.1007/s13555-022-00797-9
pubmed: 36169883
pmcid: 9588094
Tekgoz E, Colak S, Yardimci KG, Kucuksahin O, Cinar M, Yilmaz S et al (2022) Physicians’ biological drug preference in patients with rheumatoid arthritis and spondyloarthritis with a history of malignancy: perspectives from the treasure database. J Clin Rheumatol 28(2):E318–E323
doi: 10.1097/RHU.0000000000001699
pubmed: 34014053
Monsour EP, Pothen J, Balaraman R. A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report. Cureus [Internet]. 2019 Oct 2 [cited 2023 Dec 2];11(10). Available from: https://pubmed.ncbi.nlm.nih.gov/31754559/
Ma VT, Lao CD, Fecher LA, Schiopu E (2022) Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. Immunotherapy 14(8):593–598
doi: 10.2217/imt-2021-0274
pubmed: 35416067
pmcid: 9096604
Rudwaleit M, Van Der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783
doi: 10.1136/ard.2009.108233
pubmed: 19297344
Rudwaleit M, Van Der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31
doi: 10.1136/ard.2010.133645
pubmed: 21109520
Esfahani K, Miller WH (2017) Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 376(20):1989–1991
doi: 10.1056/NEJMc1703047
pubmed: 28514612
Saura SP, Casimiro LM, Vázquez AG, Benavent MP, Guillén-Climent S, Villaescusa EM (2021) Successful outcome of psoriasis in a laryngeal cancer patient treated with ixekizumab, a possible beneficial treatment for both pathologies. Dermatol Online J. https://doi.org/10.5070/D327654071
doi: 10.5070/D327654071
Vinaixa-Aranzazu A, Morillas-Lahuerta V, Blanco-De-Tord M, Carrascosa-Carrillo JM (2021) Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient. Eur J Dermatol 31(4):564–565
doi: 10.1684/ejd.2021.4087
pubmed: 34463279
pmcid: 8572685
Dong C (2008) IL-23/IL-17 biology and therapeutic considerations. J Immunotoxicol 5(1):43–46
doi: 10.1080/15476910801897953
pubmed: 18382857
Zhao J, Chen X, Herjan T, Li X (2020) The role of interleukin-17 in tumor development and progression. J Exp Med. https://doi.org/10.1084/jem.20190297
doi: 10.1084/jem.20190297
pubmed: 32496556
pmcid: 7748821